Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
SALT LAKE CITY, Jan. 21, 2016 -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, Feb. 2. During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, chief financial officer, will provide an overview of Myriad’s financial performance for the fiscal second-quarter and provide a business update.
To listen to the call, interested parties in the United States may dial 800-676-1873 or +1 303-223-4378 for international callers. All callers will be asked to reference reservation number 21802448. The conference call also will be available through a live webcast and a slide presentation pertaining to the earnings call will also be available under the investor section of our website at www.myriad.com. A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the United States or +1 402-977-9140 for international callers and entering reservation number 21802448.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where high value diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer markets, diversifying its product portfolio through the introduction of new products and increasing its international contribution. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
